Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of ZSVG-02-O mRNA COVID-19 Vaccine in Healthy Adults
NCT06113744Phase 1Recruiting
- Sponsor
- Virogin Biotech
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ZSVG-02-O in coronavirus disease 2019 (COVID-19) (9 arms), sponsored by Virogin Biotech. Primary endpoint: Number and frequency of adverse event (AE). Started Mar 2023; status: recruiting.
02
Drugs
ZSVG-02-O
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06113744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06113744.